Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model

Neuroscience

Volumn 300, Issue , 2015, Pages 585-592

  Hikishima, K ^a,b   Ando, K ^b   Komaki, Y ^a,b   Kawai, K ^b   Yano, R ^a   Inoue, T ^b   Itoh, T ^b   Yamada, M ^c   Momoshima, S ^a   Okano, H J ^d   Okano, H ^a,e  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Callithrix jacchus; Common marmoset; MPTP; Parkinson's disease; Substantia nigra; VBM

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CALLITRICHINAE; CONTROLLED STUDY; HISTOPATHOLOGY; IN VIVO STUDY; LATERAL HYPOTHALAMUS; LOCUS CERULEUS; MALE; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; VOXEL BASED MORPHOMETRY; ANATOMY AND HISTOLOGY; ANIMAL; AUTOMATED PATTERN RECOGNITION; CALLITHRIX; DEVICES; INTOXICATION; METABOLISM; ORGAN SIZE; PATHOLOGY; PROCEDURES;

ANIMALS; CALLITHRIX; MAGNETIC RESONANCE IMAGING; MALE; MPTP POISONING; ORGAN SIZE; PATTERN RECOGNITION, AUTOMATED; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84931271760     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.05.041     Document Type: Article

References (55)

1. Agosta F., Canu E., Stojkovic T., Pievani M., Tomic A., Sarro L., Dragasevic N., Copetti M., Comi G., Kostic V.S., Filippi M. The topography of brain damage at different stages of Parkinson's disease. Hum Brain Mapp 2013, 34:2798-2807.
2. Ando K., Maeda J., Inaji M., Okauchi T., Obayashi S., Higuchi M., Suhara T., Tanioka Y. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets. Psychopharmacology 2008, 195:509-516.
3. Ando K., Obayashi S., Nagai Y., Oh-Nishi A., Minamimoto T., Higuchi M., Inoue T., Itoh T., Suhara T. PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease. PLoS ONE 2012, 7:e46371.
4. Ando K., Inoue T., Itoh T. l-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model. Pharmacol Biochem Behav 2014, 127C:62-69.
5. Anik Y., Iseri P., Demirci A., Komsuoglu S., Inan N. Magnetization transfer ratio in early period of Parkinson disease. Acad Radiol 2007, 14:189-192.
6. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
7. Bihel E., Pro-Sistiaga P., Letourneur A., Toutain J., Saulnier R., Insausti R., Bernaudin M., Roussel S., Touzani O. Permanent or transient chronic ischemic stroke in the non-human primate: behavioral, neuroimaging, histological, and immunohistochemical investigations. J Cereb Blood Flow Metab 2010, 30:273-285.
8. Borghammer P., Ostergaard K., Cumming P., Gjedde A., Rodell A., Hall N., Chakravarty M.M. A deformation-based morphometry study of patients with early-stage Parkinson's disease. Eur J Neurol 2010, 17:314-320.
9. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
10. Burns R.S., Markey S.P., Phillips J.M., Chiueh C.C. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci 1984, 11(1 Suppl):166-168.
11. Burton E.J., McKeith I.G., Burn D.J., Williams E.D., O'Brien J.T. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004, 127:791-800.
12. Camicioli R., Gee M., Bouchard T.P., Fisher N.J., Hanstock C.C., Emery D.J., Martin W.R. Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. Parkinsonism Relat Disord 2009, 15:187-195.
13. Coupe P., Yger P., Prima S., Hellier P., Kervrann C., Barillot C. An optimized blockwise nonlocal means denoising filter for 3-D magnetic resonance images. IEEE Trans Med Imaging 2008, 27:425-441.
14. Cyranoski D. Marmosets are stars of Japan's ambitious brain project. Nature 2014, 514:151-152.
15. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
16. Forno L.S., Langston J.W., DeLanney L.E., Irwin I., Ricaurte G.A. Locus coeruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986, 20:449-455.
17. Genain C.P., Hauser S.L. Creation of a model for multiple sclerosis in Callithrix jacchus marmosets. J Mol Med 1997, 75:187-197.
18. Genovese C.R., Lazar N.A., Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002, 15:870-878.
19. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996, 103:987-1041.
20. Ghaemi M., Hilker R., Rudolf J., Sobesky J., Heiss W.D. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002, 73:517-523.
21. Gibb W.R., Terruli M., Lees A.J., Jenner P., Marsden C.D. The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mov Disord 1989, 4:53-74.
22. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
23. Haacke E.M., Cheng N.Y., House M.J., Liu Q., Neelavalli J., Ogg R.J., Khan A., Ayaz M., Kirsch W., Obenaus A. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005, 23:1-25.
24. Hardman C.D., Ashwell K.W.S. Stereotaxic and Chemoarchitectural Atlas of the Brain of the Common Marmoset Boca Raaton 2012, CRC Press.
25. Hikishima K., Quallo M.M., Komaki Y., Yamada M., Kawai K., Momoshima S., Okano H.J., Sasaki E., Tamaoki N., Lemon R.N., Iriki A., Okano H. Population-averaged standard template brain atlas for the common marmoset (Callithrix jacchus). Neuroimage 2011, 54:2741-2749.
26. Hikishima K., Ando K., Yano R., Kawai K., Komaki Y., Inoue T., Itoh T., Yamada M., Momoshima S., Okano H.J., Okano H. Parkinson disease: diffusion MR imaging to detect nigrostriatal pathway loss in a marmoset model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Radiology 2015, 140601.
27. Iravani M.M., Syed E., Jackson M.J., Johnston L.C., Smith L.A., Jenner P. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci 2005, 21:841-854.
28. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008, 79:368-376.
29. Jubault T., Brambati S.M., Degroot C., Kullmann B., Strafella A.P., Lafontaine A.L., Chouinard S., Monchi O. Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI. PLoS ONE 2009, 4:e8247.
30. Kendall A.L., Rayment F.D., Torres E.M., Baker H.F., Ridley R.M., Dunnett S.B. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998, 4:727-729.
31. Kikuchi T., Morizane A., Doi D., Onoe H., Hayashi T., Kawasaki T., Saiki H., Miyamoto S., Takahashi J. Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease. J Parkinsons Dis 2011, 1:395-412.
32. Lin L., Wu S., Bin G., Yang C. Intensity inhomogeneity correction using N3 on mouse brain magnetic resonance microscopy. J Neuroimaging 2013, 23:502-507.
33. Maclean C.J., Baker H.F., Ridley R.M., Mori H. Naturally occurring and experimentally induced beta-amyloid deposits in the brains of marmosets (Callithrix jacchus). J Neural Transm 2000, 107:799-814.
34. Marsden C.D. Parkinson's disease. Lancet 1990, 335:948-952.
35. Mueller S., Keeser D., Reiser M.F., Teipel S., Meindl T. Functional and structural MR imaging in neuropsychiatric disorders, Part 1: imaging techniques and their application in mild cognitive impairment and Alzheimer disease. AJNR Am J Neuroradiol 2012, 33:1845-1850.
36. Mueller S., Keeser D., Reiser M.F., Teipel S., Meindl T. Functional and structural MR imaging in neuropsychiatric disorders, part 2: application in schizophrenia and autism. AJNR Am J Neuroradiol 2012, 33:2033-2037.
37. Nagano-Saito A., Washimi Y., Arahata Y., Kachi T., Lerch J.P., Evans A.C., Dagher A., Ito K. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005, 64:224-229.
38. Okano H., Mitra P. Brain-mapping projects using the common marmoset. Neurosci Res 2014.
39. Okano H., Hikishima K., Iriki A., Sasaki E. The common marmoset as a novel animal model system for biomedical and neuroscience research applications. Semin Fetal Neonatal Med 2012, 17:336-340.
40. Okano H., Miyawaki A., Kasai K. Brain/MINDS: brain-mapping project in Japan. Philos Trans R Soc Lond B Biol Sci 2015, 370(1668). 10.1098/rstb.2014.0310.
41. O'Neill J., Schuff N., Marks W.J., Feiwell R., Aminoff M.J., Weiner M.W. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002, 17:917-927.
42. Paxinos G., Watson C., Petrides M., Rosa M., Tokuno H. The Marmoset Brain in Stereotaxic Coordinates 2011, Academic Press, London.
43. Pujol J., Junque C., Vendrell P., Grau J.M., Capdevila A. Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease. Arch Neurol 1992, 49:1119-1122.
44. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., Jenkins B.G., Goldstein J.M. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
45. Sasaki M., Shibata E., Tohyama K., Takahashi J., Otsuka K., Tsuchiya K., Takahashi S., Ehara S., Terayama Y., Sakai A. Neuromelanin magnetic resonance imaging of locus coeruleus and substantia nigra in Parkinson's disease. NeuroReport 2006, 17:1215-1218.
46. Sasaki E., Suemizu H., Shimada A., Hanazawa K., Oiwa R., Kamioka M., Tomioka I., Sotomaru Y., Hirakawa R., Eto T., Shiozawa S., Maeda T., Ito M., Ito R., Kito C., Yagihashi C., Kawai K., Miyoshi H., Tanioka Y., Tamaoki N., Habu S., Okano H., Nomura T. Generation of transgenic non-human primates with germline transmission. Nature 2009, 459:523-527.
47. Sawiak S.J., Picq J.L., Dhenain M. Voxel-based morphometry analyses of in vivo MRI in the aging mouse lemur primate. Front Aging Neurosci 2014, 6:82.
48. Schulz J.B., Skalej M., Wedekind D., Luft A.R., Abele M., Voigt K., Dichgans J., Klockgether T. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999, 45:65-74.
49. Sled J.G., Zijdenbos A.P., Evans A.C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998, 17:87-97.
50. Smith S.M. Fast robust automated brain extraction. Hum Brain Mapp 2002, 17:143-155.
51. Takagi Y., Takahashi J., Saiki H., Morizane A., Hayashi T., Kishi Y., Fukuda H., Okamoto Y., Koyanagi M., Ideguchi M., Hayashi H., Imazato T., Kawasaki H., Suemori H., Omachi S., Iida H., Itoh N., Nakatsuji N., Sasai Y., Hashimoto N. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 2005, 115:102-109.
52. Waters C.M., Hunt S.P., Jenner P., Marsden C.D. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Neuroscience 1987, 23:1025-1039.
53. Wattendorf E., Welge-Lussen A., Fiedler K., Bilecen D., Wolfensberger M., Fuhr P., Hummel T., Westermann B. Olfactory impairment predicts brain atrophy in Parkinson's disease. J Neurosci 2009, 29:15410-15413.
54. Yamada M., Momoshima S., Masutani Y., Fujiyoshi K., Abe O., Nakamura M., Aoki S., Tamaoki N., Okano H. Diffusion-tensor neuronal fiber tractography and manganese-enhanced MR imaging of primate visual pathway in the common marmoset: preliminary results. Radiology 2008, 249:855-864.
55. Zhang J., Zhang Y., Wang J., Cai P., Luo C., Qian Z., Dai Y., Feng H. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res 2010, 1330:124-130.